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Background. Antimicrobial drug resistance is a global threat for treatment of infectious diseases and costs life and money and
threatens health delivery system’s effectiveness. The resistance of E. coli to frequently utilized antimicrobial drugs is becoming
a major challenge in Ethiopia. However, there is no inclusive countrywide study. Therefore, this study intended to assess the
prevalence of E. coli resistance and antimicrobial-specific resistance pattern among E. coli clinical isolates in Ethiopia. Methods.
Articles were retrieved from PubMed, Embase, and grey literature from 2007 to 2017. The main outcome measures were overall E.
coli and drug-specific resistance patterns. A random-effects model was used to determine pooled prevalence with 95% confidence
interval (CI), using DerSimonian and Laird method. In addition, subgroup analysis was conducted to improve the outcome.
The study bias was assessed by Begg’s funnel plot. This study was registered in PROSPERO as follows: PROSPERO 2017:
CRD42017070106. Results. Of 164 articles retrieved, 35 articles were included. A total of 19,235 study samples participated in the
studies and 2,635 E. coli strains were isolated. Overall, E. coli antibacterial resistance was 45.38% (95% confidence interval (CI):
33.50 to 57.27). The resistance pattern ranges from 62.55% in Addis Ababa to 27.51% in Tigray region. The highest resistance of
E. coli reported was to ampicillin (83.81%) and amoxicillin (75.79%), whereas only 13.55% of E. coli isolates showed resistance to
nitrofurantoin. Conclusion. E. coli antimicrobial resistance remains high with disparities observed among regions. The bacterium
was found to be highly resistant to aminopenicillins. The finding implies the need for effective prevention strategies for the E. coli
drug resistance and calls for multifaceted approaches with full involvement of all stakeholders.
1. Background
Escherichia coli (E. coli) is one of themost widespread bacteria
throughout the world. Some strains of E. coli can cause
serious illness for humankind [1] including urinary tract
infections [2–4], bloodstream infections [5], skin infection,
otitis media [6, 7], and diarrhea [8].
E. coli resistance to antimicrobials is creating trouble to
the healthcare system worldwide [9, 10]. This complicates
treatment outcomes, increases the cost of treatment, and
limits the therapeutic options that contribute to the global
spectra of a postantimicrobial age in which some of the most
effective drugs lose their efficiency [11]. The bacterium is
becoming highly resistant to conventionally used antibiotics
(to both the newer and older medicines) as evidenced by
many previous studies [12–16]. Adaptive resistance was sup-
posed to be the main mechanism for the development of
resistance including that to lethal doses of the antimicrobials
[17].
Antimicrobial resistance of E. coli in developing countries
including Ethiopia is reported to be one major reason for
failure of treatment of infectious diseases [18]. A number of
studies conducted in Ethiopia from various clinical settings
show increments in the prevalence of antimicrobial resistance
patterns of E. coli [6, 19, 20]. However, there is no compre-
hensive and aggregated nationwide study to show the pattern
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Table 1: Searching strategies including search arm and terms used in the study.
Search arm Search terms
1 E. coli “Escherichia coli” OR “E. coli”
2 Drug and/orresistance
“antibiotic resistance” OR “drug resistance” OR “drug
resistance, microbial” OR “drug resistance, microbial”
OR “antibacterial resistance” OR “antibiotic resistance”
OR “antimicrobial resistance”
3 Ethiopia “Ethiopia”
The word “OR” was used to combine search terms within each arm and the word “AND” was used to connect the three search arms (#1 AND #2 AND #3).
of antimicrobial resistance in E. coli. Hence, the purpose of
this meta-analysis was to sum up the available data and to
establish the pooled prevalence and antimicrobial resistance
of E. coli in Ethiopia.
2. Methods
This study was conducted in a similar approach to Eshetie
et al. (2016) [21] and according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analysis (PRISMA)
Checklist [22] (additional S1 file).
2.1. Study Selection. A systematic literature search was con-
ducted in PubMed and Embase, and also manual search
for articles potentially relevant to our study was identi-
fied. We built our search strategy by combining the three
main arms (Table 1): E. coli, drugs-related terms, and Ethio-
pia.
Among the citations extracted, abstracts were reviewed
to retrieve the clinical studies on E. coli colonization. Articles
that were relevant, by title and abstract, were accessed in full
text to determine those that provided sufficient information
to be included in our meta-analysis. Finally, the references
cited by each eligible study were screened to identify addi-
tional articles.
2.2. Inclusion and Exclusion Criteria. Studies included in
this meta-analysis were those that had extractable data on
the prevalence of drug resistance of E. coli on a human
in Ethiopian hospitals or research centers and were only
published from 2007 to 2017 and were only in English
language.
2.3. Outcome of Interest. The main outcome of interest was
the prevalence of drug resistance or antimicrobial suscep-
tibility of E. coli among the total E. coli clinical isolates.
The prevalence was calculated by dividing the numbers of
resistant E. coli isolates by the total number of clinically
isolated E. coli. As a secondary outcome of interest, we had
also calculated the pooled resistance pattern of E. coli isolates
to specific antibiotics.
2.4. Data Extraction and Assessment of Quality of Study.
Screening by title, abstract, and full text and data extraction
were done independently by two authors (Kald Beshir Tuem
and Abadi Kahsu Gebre) at each step and Derbew Fikadu
Berhe was involved in consensus for discrepancies (if any)
between the two authors (Kald Beshir Tuem andAbadi Kahsu
Gebre). In cases of insufficient data, the authors reviewed the
full text of the article for further information and clarification.
The extracted data from each article were summarized into
a spreadsheet. References and data for each study were
carefully cross-checked to ensure that no overlapping data
were present and to maintain the integrity of the meta-
analysis. Information extracted from each paper was region,
study area, study design, study population, culture specimens,
number of E. coli isolated, the average percentage of resistant
E. coli, antimicrobial resistance rate of E. coli, and references.
With all the articles used in this study being cross-sectional,
the score for the quality of the study was assessed using the
modified Newcastle-Ottawa scale for the representativeness
of sample, appropriateness of sample size, response rate,
validity of method, strategy to control confounding factors,
reliability of outcome determination, and appropriate statis-
tical analyses.The quality score (Table 2) disagreements were
resolved by consensus and a final agreed-upon rating was
assigned to each study (S2 file) [58].
2.5. Quality Control. The quality of eligible studies was
checked independently by two authors (Kald Beshir Tuem
andAbadi KahsuGebre) using a set of predetermined criteria
such as research design quality of paper, completeness of
extractable information, and employed methods for E. coli
isolation. The study bias was measured by Begg’s funnel plot
[59]. This study was registered in PROSPERO as follows:
PROSPERO 2017: CRD42017070106.
2.6. Data Analysis. A random-effects model was used to
determine pooled prevalence, subgroup analysis, and 95%
confidence interval (CI) by employing the approach of Der-
Simonian and Laird [60]. Variances and CIs were stabilized
using Freeman-Tukey arc-sine methodology [61]; the reason
is that using the standard approach of inverse variance
method to calculate pooled prevalence does not work well
in meta-analysis of single-arm study because, for studies
with small or large prevalence, the inverse variance method
causes the variance to become small and the calculated CI
may be outside of the range [62]. Heterogeneity of study
results was assessed using 𝐼2 test and significant heterogeneity
was considered at 𝑝 < 0.10 and 𝐼2 > 50% [60, 63].
Statistical analyses were performed usingOpenMeta-Analyst
(version 3.13) and Comprehensive Meta-Analysis (version
3.1). In addition, we performed subgroup analyses according
to the region of the country and the mechanism of action
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EMBASE (n = 77) 
Duplication (n = 77)
Full text screened (n = 56)
Excluded (n = 21)
Not on human population and studied before 2007
Included papers (n = 35) 
Title/abstract screened (n = 81)
PubMed (n = 75) 
Grey literature/back 
reference (n = 6) 
Incomplete data or full content of the
article not found (n = 25)
Figure 1: Flowchart shows selected articles for meta-analysis.
of the tested drugs to improve the specificity of the assess-
ment.
3. Results
From Embase, PubMed, andmanual searching, we found 164
potentially relevant studies, of which 35 were included for
analysis (Figure 1).
The study design of all included articles (35) was cross-
sectional study. In these studies, a total of 19,235 study
samples participated, from which 2,635 E. coli strains were
isolated. The published studies were from four regions in
Ethiopia (Table 2) which include the federal capital city
of Ethiopia, Addis Ababa. No report was obtained from
other regions in the country (Afar, Benishangul-Gumuz,
Gambella, and Somali). Most of the studies indicated that
various specimens had been utilized for screening of E. coli;
particularlymultisite swabbing was performed from different
parts of the body, including skin, nasal, eye, ear, urethra,
throat, vagina, or genital area (Table 2), and other biological
fluids like blood, urine, pus, stool, and cerebrospinal fluid
(CSF) were taken for test. A total of 2,635 E. coli strains
were isolated from these various sites.The lowest and highest
proportions of E. coli resistance were reported, respectively,
from Bahir Dar (55.20%) and Mekelle (27.50%) cities. The
average prevalence of E. coli resistance was also noted in
different regions of Ethiopia; Addis Ababa region was ranked
first (62.55%, 95% CI: 38.28–6.83%), followed by Southern
Nations, Nationalities, and Peoples of Ethiopia (58.14%, 95%
CI: 48.69–67.58%), Amhara (47.83%, 95% CI: 39.77–55.89%),
and Oromia (42.86%, 95% CI: 32.77–52.95%), whereas rela-
tively low magnitude of E. coli resistance was reported from
Tigray region (27.51%, 95% CI: 16.14–38.88%) (Figures 2 and
3).
Subgroup analyses (Figure 3) were carried out based
on the region (Addis Ababa, Amhara, Oromia, SNNP, and
Tigray) and the mechanism of action of the drugs (cell
wall synthesis inhibitors, protein synthesis inhibitors, DNA
synthesis inhibitors, and antimetabolites). A paper-based
analysis in our study showed that the overall E. coli resistance
in Ethiopia was 48.87% (95% CI: 42.17–55.57%) with highest
prevalence in the capital city, Addis Ababa, 62.55% (95% CI:
38.28–86.83%) (Figure 3).
As presented in Figure 4 and Table 3, the pooled prev-
alence of E. coli resistance was 45.38% (95% CI: 33.50–
57.27%), and high resistance rates were observed to am-
picillin, 83.81% (95% CI: 76.95–90.67%), amoxicillin, 75.79%
(95% CI: 64.26–87.32%), tetracycline, 67.18% (95% CI: 58.89–
75.47%), trimethoprim-sulfamethoxazole, 57.47% (95% CI:
58.89–75.47%), and cephalothin, 56.69% (95% CI: 33.74–
79.64%). A relatively low level of nitrofurantoin resistance
was observed, 13.55% (95% CI: 5.83–21.27%).
Comparing the prevalence of E. coli resistance among
the antibacterial drugs, subgroup analysis (Figure 5) revealed
that the cell wall synthesis inhibitors account for the greatest
resistance percentage, 59.37% (95% CI: 36.21–82.53%), and
DNA synthesis inhibitors account for the lowest resistance
percentage, 26.14% (95% CI: 33.50–57.27%).
There was a high level of heterogeneity by randommodel
methods (𝐼2 = 97.89%; 𝑝 < 0.01). Hence, the included
studies have been conducted in different study settings,
study periods, and study populations, which could have
an effect on the heterogeneity of the included studies. The
symmetry of funnel plot showed small study bias, which
yielded insignificant effect.
4. Discussion
Antibiotic resistance continues to be amajor global challenge
in the management of bacterial infection.The trouble behind
antibiotic resistance is highly marked in undeveloped or
developing countries, including Ethiopia, where infectious
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2: Proportion ofE. coli resistance in different regions of Ethiopia, 2007–2017. Values in parenthesis indicated 95%CI ofE. coli resistance
in different regions of Ethiopia.
diseases are highly prevalent [64]. Factors responsible for
an increase in rates of antimicrobial resistance include mis-
use/overuse of antibiotics by healthcare professionals and
general public and inadequate surveillance systems due to
lack of reliable microbiological techniques leading to the
inappropriate prescription of antibiotics [33]. Antimicrobial
resistance in E. coli has increased worldwide and its sus-
ceptibility patterns show substantial variation in different
geographical locations [5]. To date, the overall epidemiology
and burden of multidrug resistance (MDR) bacteria have
not been fully understood, especially in resource-limited
countries including Ethiopia [64, 65]. To the best of our
knowledge, this is the first meta-analysis study conducted
to determine the pooled prevalence of E. coli prevalence
and resistance in Ethiopia. Our result revealed that E. coli
strains displayed diverse resistance patterns, with percentages
varying slightly based on sample type and geographical
distribution. Based on the tested antimicrobials, the overall
E. coli resistance in Ethiopia was nearly 50% (45.38% (95%
CI: 33.50–57.27%)).
Developing countries have comparatively higher risk
factors associated with MDR strains than the developed
ones [64, 66]. Resistance to antibacterial agents is a normal
evolutionary process for microorganisms, but it is highly
aggravated by continuous deployment of antimicrobial drugs
in treating infections [67, 68]. It is claimed that more than
half of drugs are prescribed, sold, or dispensed without
following standard protocols, and the situation is more
pronounced in developing countries including Ethiopia [69].
Sosa et al. (2010) reported that antibiotic usage in most of
the low-income countries is generally unregulated, which
is a prime factor for the occurrence of resistant bacte-
rial strains [64]. This implies that antibiotics are being
used widely and inappropriately in resource-limited coun-
tries including Ethiopia. This may lead to an increase in
the occurrence of drug-resistive bacterial strains such as
E. coli.
In our study, the regional prevalence of E. coli resistance
was estimated, and the subgroup analysis showed that the
highest prevalence of E. coli resistance (62.55%) was noted
in Addis Ababa city, which was almost two times higher
than Tigray region (27.51%). The observed variation might
be due to differences in study location, hospital setup, and
antimicrobial utilization.
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Figure 3: Subgroup analysis of E. coli antibacterial resistance according to regions of Ethiopia.
Subgroup analysis also showed that E. coli strains exhib-
ited higher resistance with cell wall inhibitors, specifically
aminopenicillins (ampicillin and amoxicillin), followed by
protein synthesis inhibitors, mainly to tetracycline, and lesser
resistance prevalence to nitrofurantoin. In line with our data,
globally, E. coli strains were reported to be highly resistant to
the above-mentioned antibiotics, mainly to aminopenicillins
[70, 71]. Săndulescu (2016) reported that E. coli showed low
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13.55 (5.83, 21.27) 
45.38 (33.50, 57.27) 
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Overall (I2 = 94.89%,p < 0.01)
Figure 4: Forest plot of the pooled percentage and confidence interval of E. coli resistance to antibacterial drugs in Ethiopia from 2007 to
2017.
resistance to nitrofurantoin, which is in line with the present
finding.
Moreover, our finding indicated the higher magnitude of
E. coli resistance.This may imply the need for intervention in
prescribing and using antibacterial against E. coli infections.
Interventional strategies may include creating public aware-
ness, maintaining hand hygiene, applying infection preven-
tion protocols, and maintaining environmental sanitation,
which are encouraged for preventing infection. In addition to
these, promoting health education, maintaining continuous
professional educations, and advocating rational prescribing
habits are evidently effective in the minimization of the
unwanted use of antibiotics, which in turn decrease selective
pressure of resistant strains.
5. Conclusion
In thismeta-analysis, the pooled E. coli resistance is consider-
ably high. E. coli strains were highly resistant to ampicillin but
showed lesser resistance to nitrofurantoin. Adopting safety
protocols and implementing proper antibiotic prescription
policies could be potential interventional strategies to address























R: Retrospective review of culture
RCS: Retrospective cross-sectional




UTI: Urinary tract infection.
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Overall (I2 = 94.89%, p = 0.00)
(I2 = 75.17%, p = 0.01)
(I2 = 89.67%, p = 0.00)
(I2 = 94.9%, p = 0.00)
Subgroup Anti-metabolite (I2 = NA
p = NA)
20 40 60 80
Figure 5: Subgroup analysis of pooled percentage and confidence interval of E. coli resistance to antibacterial drugs according to drug
mechanism of action.
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Supplementary 1. S1 file: PRISMA 2009 Checklist. We have
conducted the meta-analysis according to Moher et al.
(2009), “Preferred Reporting Items for Systematic Reviews
and Meta-Analyses: The PRISMA Statement.” We included
all the criteria on the checklist, except in the discussion part;
we did not include the limitations of the study related to
incomplete retrieval of articles, as we did not face such a
problem.
Supplementary 2. S2 file: Modified Newcastle-Ottawa Scale.
This scale had been adapted from Wells et al. (2009), “The
Newcastle-Ottawa Scale (NOS) for Assessing the Quality of
Nonrandomized Studies in Meta-Analyses.” We considered
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the comparability to be controlled if the standard laboratory
procedure is described in the articles. Since the outcome of
the bacterial sensitivity test is obtained after full growth of
the bacterial strains, we assigned one star for the assessment
outcomes of all studies.
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